Appointment of Alex Hughes as CFO

RNS Number : 4157R

BiVictriX Therapeutics PLC

01 March 2023

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED.  ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

BIVICTRIX THERAPEUTICS PLC

("BiVictriX" or the "Company")

Appointment of Alex Hughes as Chief Financial Officer

Alderley Park, 1^st March 2023 - BiVictriX Therapeutics plc (AIM: BVX), an emerging biotechnology company applying a novel approach to develop next-generation cancer therapies with improved tolerability and anti-cancer activity, today announces that it has appointed Alex Hughes as Chief Financial Officer. Glyn Baker will be stepping down from the position on 31^st March.

Alex has held senior finance and operational positions in listed global companies for 10 years, developing and implementing strong control environments whilst working with leadership teams to achieve strategic company goals.  Most recently, Alex has contributed to the growth of a US listed biotechnology company, Instil Bio Inc., as finance director. Previously, he held roles at Argent Energy and Luxfer MEL Technologies.

Tiffany Thorn, Chief Executive of BiVictriX, commented: "We look forward to working with Alex as we enter this new period of growth following our recent positive preclinical safety results of BVX001. I am confident that his extensive financial experience will help guide the Company, as we continue to make great progress in the development of our urgently-needed next-generation therapeutics. I would personally like to thank Glyn for his dedication and much valued support during his time with us."

Alex Hughes, BiVictriX's incoming Chief Financial Officer, added: "I am delighted to be joining the BiVictrix team.  I believe the Company's potential to develop next generation cancer therapies for patients is tremendous and I look forward to being part of such a talented and passionate team.  Having previously supported similar leadership teams, I am confident that we can continue our growth and achieve our objectives." 

For more information, please contact: BiVictriX Therapeutics plc Tiffany Thorn, Chief Executive Officer Michael Kauffman, Non-Executive Chairman Email:  [e-mail] SP Angel Corporate Finance LLP (NOMAD and Broker) Tel: [phone] David Hignell, Kasia Brzozowska (Corporate Finance) Vadim Alexandre, Rob Rees (Sales and Broking) Panmure Gordon (UK) Limited (Joint Broker) Tel: [phone] Rupert Dearden/Freddy Crossley/Emma Earl Consilium Strategic Communications Mary-Jane Elliott, Namrata Taak, Genevieve Wilson, Alex Gunter Tel: [phone] Email:  [e-mail]

About BiVictriX Therapeutics plc

BiVictriX is a UK-based drug discovery and development company which is focused on leveraging clinical experience to develop a new class of highly selective, next generation cancer therapeutics which exhibit superior potency, whilst significantly reducing treatment-related toxicities.

The Company utilises a first-in-class approach to generate a proprietary pipeline of Bi-Cygni® Antibody Drug Conjugate therapeutics which are designed to selectively target cancer-specific antigen pairs, or "Bi-Cygni® fingerprints", on tumour cells, which are largely absent from healthy cells.

BiVictriX has established a growing proprietary library of cancer-specific Bi-Cygni® fingerprints, which enable the Company to target a diverse array of different cancer types. The Company utilises these novel Bi-Cygni® fingerprints, together with the Company's novel Antibody Drug Conjugate therapeutic design, to develop more effective and safer therapeutics to target cancers that are expected to constitute orphan indications and areas of high unmet medical need.

Find out more about BiVictriX online at  www.bivictrix.com    

 

END

 

 

MSCSEEFUAEDSELE